Sun Pharmaceutical Industries · NSE: SUNPHARMA · BSE: 524715

Q4 FY22 results · Jan–Mar 2022

Sun Pharmaceutical Industries reported revenue from operations of ₹9,446.76 crore (up 10.8% from Q4 FY21) and net loss of ₹2,227.38 crore for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY22	Q4 FY21	YoY	Q3 FY22	QoQ
Revenue from operations	9,446.76	8,522.98	+10.8%	9,863.06	−4.2%
Other income	113.59	111.00	+2.3%	432.51	−73.7%
Total income	9,560.35	8,633.98	+10.7%	10,295.57	−7.1%
Profit before share of associates & JVs and tax	(2,075.60)	903.04	Turned loss	2,466.19	Turned loss
Share of profit/(loss) of associates & JVs	(5.02)	(5.59)		(4.52)
Net profit for the period	(2,227.38)	842.41	Turned loss	2,126.28	Turned loss
Attributable to shareholders of the company	(2,277.25)	894.15	Turned loss	2,058.80	Turned loss
EPS, basic (₹)	(9.50)	3.70	Turned loss	8.60	Turned loss
Net margin (%)	-23.6	9.9		21.6

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY22	Q4 FY21	YoY	Q3 FY22	QoQ
Revenue from operations	4,006.88	3,159.64	+26.8%	3,770.66	+6.3%
Other income	300.41	34.87	+761.5%	305.23	−1.6%
Total income	4,307.29	3,194.51	+34.8%	4,075.89	+5.7%
Profit before tax	(800.04)	371.07	Turned loss	520.91	Turned loss
Net profit for the period	(1,286.21)	327.39	Turned loss	515.43	Turned loss
EPS, basic (₹)	(5.40)	1.36	Turned loss	2.10	Turned loss
Net margin (%)	-32.1	10.4		13.7

Consolidated

Filed with BSE: 31 May 2022, 15:46 IST
Board meeting: 30 May 2022
Period: 01 Jan 2022 to 31 Mar 2022
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 31 May 2022, 15:46 IST
Board meeting: 30 May 2022
Period: 01 Jan 2022 to 31 Mar 2022
Review status: Audited
Source: XBRL filing on BSE